# Genewise Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genewise-bio

- Industry: Biotechnology
- Headquarters: Beijing, China
- Total disclosed funding: $14M
- Latest round: Series A (Jun 4, 2024)
- Investors on record: 4

## About

Established in 2021 and based in Beijing, China, Genewise Bio is a medical testing services company with a primary focus on molecular testing. The company was incubated by BOE Technology Group, and has developed an integrated R&D and production system for microfluidic chips, diagnostic reagents, and testing equipment. The team at Genewise Bio consists of talents from institutions such as Princeton, Tsinghua, Peking University, and the Chinese Academy of Sciences. The company has received Class III medical device registration certificates and CE certification from the National Medical Products Administration (NMPA) for over 20 products. In June 2024, the company raised CNY 100 million in a round of series A funding.

The company offers a range of POCT molecular diagnostic platforms, including pathogen detection, antimicrobial resistance gene testing, and women's and children's health. Key products include the NAT-3000 fully automatic nucleic acid amplification analyzer and the new coronavirus (2019-nCov) and influenza A/B nucleic acid combined detection kit (fluorescent PCR method). The above products have been approved for marketing and have been installed in a number of tertiary hospitals and children's medical centers in various regions.

The company generates revenue by selling its diagnostic products and providing related services, targeting hospitals, medical centers, and laboratories.

The company will use the series A funding raised in June 2024 to accelerate its POCT molecular diagnostics products' domestic and international commercialization process.

## Funding rounds

- Series A, Jun 4, 2024, $14M — Aeonmed, Tsing Song Capital, SH Pinnacles, Zhejiang Wuhe Investment Management

## Investors

- Aeonmed — Series A
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series A
- SH Pinnacles — Series A
- Zhejiang Wuhe Investment Management — Series A